Freedom of Information Summary, NADA 121-473, supplemental approval (PANACUR-C, Rx to OTC) (2002)

Government Record · U.S. Food and Drug Administration, Center for Veterinary Medicine; sponsor Intervet Inc. · March 19, 2002

U.S. Food et al., 2002-03-19: FDA freedom-of-information summary for the supplement that moved Panacur-C 22.2% granules from prescription to over-the-counter in dogs. It records that the original 1983 approval was restricted to prescription status over a concern about undiscovered hepatotoxicity, and that post-marketing experience did not show a pattern of liver disease.

At the time of original approval this drug product received prescription status because of concern that fenbendazole may have some undiscovered hepatotoxic effects in dogs.

3

U.S. Food et al., 2002-03-19: FDA freedom-of-information summary for the supplement that moved Panacur-C 22.2% granules from prescription to over-the-counter in dogs. It records that the original 1983 approval was restricted to prescription status over a concern about undiscovered hepatotoxicity, and that post-marketing experience did not show a pattern of liver disease. Regulatory record, not a study. Species: dogs. Dose regimen on the label: 50 mg/kg daily for 3 days. Funder: FDA review of sponsor (Intervet) data. Comparator: none. Bearing PARTLY SUPPORTS because the document confirms a hepatotoxicity concern existed at approval while also recording that marketing experience did not confirm it: it supports the claim that regulatory toxicology includes liver findings, but not that the drug was shown to be hepatotoxic in dogs at label dose. Excerpt is on PDF page 3 of a 3-page summary (the PDF has 5 sheets because of blank pages). Date 2002-03-19 is from the FDA application record; the FOI summary prints only the 27 October 1983 original approval date. Study type: regulatory record.